Vistagen’s Repeat-Dose Study Supports Fasedienol’s Potential in Social Anxiety Disorder

Key Points

• Vistagen reported topline results from an exploratory Phase 2 repeat‑dose study of fasedienol nasal spray for the acute treatment of social anxiety disorder.
• Two doses given ahead of a public speaking challenge showed a safety and tolerability profile similar to prior single‑dose use, with no new safety concerns.
• Numerical efficacy signals were observed across key anxiety and global improvement measures, reinforcing earlier positive findings from the PALISADE program.

Vistagen Therapeutics (NASDAQ: VTGN) is continuing to build its case for fasedienol as a rapid‑acting, on‑demand treatment option for social anxiety disorder. The company has announced topline results from a Phase 2 repeat‑dose study, designed to explore whether giving two doses of fasedienol before an anxiety‑provoking situation can provide added benefit while maintaining the strong safety profile seen in earlier trials.

 How the repeat‑dose study was designed

The repeat‑dose study enrolled adults with social anxiety disorder and used a standardized public speaking challenge to trigger acute anxiety. Participants were randomized to receive either fasedienol or placebo as a nasal spray—one dose 20 minutes before the challenge and a second dose 10 minutes later. The main outcome measure was the Subjective Units of Distress Scale (SUDS), a patient‑reported rating of moment‑to‑moment anxiety from 0 (no distress) to 100 (extreme distress). Additional measures included clinician‑rated global improvement (CGI‑I) and patient global impression of change (PGI‑C), which help capture overall perceived benefit.

 Safety and tolerability remain favorable with repeat dosing

According to Vistagen, repeat dosing of fasedienol in this study was well tolerated, with a safety profile similar to single‑dose use. No new drug‑related safety signals were identified, and adverse events were generally mild or moderate. These findings are consistent with data from PALISADE‑3’s open‑label extension, where patients used fasedienol as needed up to six times per day over many months without serious safety concerns emerging. Taken together, the data suggest that fasedienol can be used in real‑world settings requiring repeat or intermittent dosing without compromising tolerability.

 Encouraging efficacy signals across anxiety measures

While the repeat‑dose study was relatively small and exploratory, Vistagen reports numerical improvements favoring fasedienol over placebo on the SUDS scale and related global improvement measures. These signals build on prior results from PALISADE‑2, where a single dose of fasedienol before a public speaking challenge led to a statistically significant reduction in SUDS scores versus placebo and higher responder rates on CGI‑I and PGI‑C. Although some earlier trials in the PALISADE program did not meet their primary endpoints, subsequent analyses and subgroup data have shown that fasedienol may deliver meaningful anxiety relief when used in specific dosing contexts and patient populations.

 Role of the repeat‑dose data in Vistagen’s broader program

The repeat‑dose study is part of Vistagen’s ongoing Phase 3 PALISADE program, which includes multiple randomized trials and open‑label extensions aimed at understanding how fasedienol performs in both controlled challenges and everyday life. Vistagen has already achieved regulatory safety exposure targets recommended by ICH guidelines for drugs used repeatedly over time, thanks to combined data across these studies. The new repeat‑dose results will help refine future trial designs and may inform how clinicians eventually use fasedienol—potentially as one or more doses given shortly before anxiety‑provoking social events.

 Takeaways for VTGN investors

For VTGN investors, the topline repeat‑dose results indicate that fasedienol continues to show a clean safety profile and encouraging signals of benefit in social anxiety disorder, even when two doses are given close together before a stressful event. The program’s mixed history means that definitive proof of efficacy will still depend on upcoming Phase 3 readouts and regulatory review, but Vistagen is steadily building a more detailed picture of where and how the drug works best. If future data confirm these signals, fasedienol could occupy a differentiated niche as a rapid‑onset, event‑based treatment that complements longer‑term therapies for social anxiety.